Results 161 to 170 of about 47,712 (207)
Some of the next articles are maybe not open access.
GLP-1 receptor agonists in NAFLD
Diabetes & Metabolism, 2017Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (
Petit, Jean-Michel, Vergès, Bruno
openaire +2 more sources
Emerging GLP-1 receptor agonists
Expert Opinion on Emerging Drugs, 2011Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become available for the treatment of type 2 diabetes. These agents exploit the physiological effects of GLP-1, which is able to address several of the pathophysiological features of type 2 diabetes.
Lund, Asger +2 more
openaire +3 more sources
Diabetes Research and Clinical Practice, 2011
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications.
Michel, Marre, Alfred, Penfornis
openaire +2 more sources
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications.
Michel, Marre, Alfred, Penfornis
openaire +2 more sources
The Diabetes Educator, 2015
Purpose Type 2 diabetes (T2D) imparts an increased risk of adverse health outcomes in patients unable to achieve glycemic control. Patient education and individualization of treatment are important for effective management of T2D. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of injectable glucose-lowering agents that lower A1C with ...
Curtis, Triplitt +1 more
openaire +2 more sources
Purpose Type 2 diabetes (T2D) imparts an increased risk of adverse health outcomes in patients unable to achieve glycemic control. Patient education and individualization of treatment are important for effective management of T2D. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of injectable glucose-lowering agents that lower A1C with ...
Curtis, Triplitt +1 more
openaire +2 more sources
RCSB Protein Data Bank
ABSTRACT Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting millions of individuals worldwide. The burden of disease is significant, as demonstrated by high morbidity and mortality and billions of healthcare dollars spent. The pathophysiology of T2DM is complex, with eight primary deficits.
+5 more sources
ABSTRACT Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting millions of individuals worldwide. The burden of disease is significant, as demonstrated by high morbidity and mortality and billions of healthcare dollars spent. The pathophysiology of T2DM is complex, with eight primary deficits.
+5 more sources
Novel GLP-1 receptor agonists for diabetes
Expert Opinion on Investigational Drugs, 2011GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was approved in the mid-2000s, other agents with longer durations of action (that do not require twice-daily dosing) are now being developed.
openaire +2 more sources
Albiglutide: a unique GLP-1 receptor agonist
Expert Opinion on Biological Therapy, 2016Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval ...
openaire +2 more sources
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Postgraduate Medicine, 2014Albiglutide is a glucagon-like peptide-1 analogue composed of tandem copies of modified human glucagon-like peptide-1 (7-36) coupled to recombinant human albumin that is approved in adults for the treatment of type 2 diabetes mellitus. After subcutaneous administration, albiglutide is likely primarily absorbed via the lymphatic circulation, with ...
Malcolm A, Young +6 more
openaire +2 more sources
Gastrointestinal Motility Effects of GLP-1 Receptor Agonists
Current Gastroenterology ReportsThis review summarizes the current understanding of the physiologic influence of GLP-1 RAs on gastrointestinal motility, highlights key clinical implications of these effects, and defines areas for future investigation.Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of diabetes and obesity and are increasingly ...
Danielle Bellavance +2 more
openaire +2 more sources
Effect of GLP-1 receptor agonists on body composition
Current Opinion in Endocrinology, Diabetes & ObesityPurpose of review Obesity is present in up to 85% of individuals with type 2 diabetes mellitus (T2DM) and poses a major therapeutic challenge. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for T2DM, are now widely used for obesity management and increasingly recognized for their ...
Akhila, Bhandarkar +2 more
openaire +2 more sources